This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (124)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Frederick L. Ferris III, MD

JAMA. 1993;269(10):1290-1291.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ANALYSIS of data from four decades of clinical research demonstrates that currently recommended treatments are considerably more effective in preventing blindness from proliferative diabetic retinopathy (PDR) than has been previously appreciated. In fact, careful follow-up, timely photocoagulation, and vitrectomy when necessary strikingly reduce the risk of blindness for patients with PDR. This remarkable finding lends even greater urgency to current efforts to ensure that virtually all persons with diabetes receive at least yearly dilated eye examinations and are offered appropriate treatment when indicated.

Based on the results of clinical trials supported by the National Eye Institute and extensive clinical experience, specific recommendations have been developed concerning for whom and when treatment is appropriate.^1-5 Prior to the availability of these treatments, the development of PDR was reason for extreme concern by both patients and their physicians about the risk of impending blindness. A 1963 study by Beetham⁶ showed that . . . [Full Text PDF of this Article]

Author Affiliations
From the Clinical Trials Branch, National Eye Institute, Bethesda, Md.

Footnotes
Reprint requests to the Clinical Trials Branch, National Eye Institute, Bldg 31, Room 6A24, 9000 Rockville Pike, Bethesda, MD 20892 (Dr Ferris).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?